What does Cosentyx prescribing info say about pausing for side effects?
Cosentyx (secukinumab) package insert advises discontinuing use immediately for serious infections or hypersensitivity reactions, such as anaphylaxis. For active serious infections, pause until resolved. No fixed "pause duration" exists—instead, assess resolution clinically and consult a doctor before restarting.[1]
Common side effects and when to hold doses
Mild upper respiratory infections or diarrhea often don't require pausing; continue unless worsening. For moderate infections (e.g., oral candidiasis), hold until cleared. Inflammatory bowel disease flare-ups warrant permanent discontinuation. Always monitor; restart only if benefits outweigh risks.[1][2]
How long to wait before restarting after pausing?
Duration varies by side effect severity:
- Mild infections: 1-2 weeks post-resolution, per physician guidance.
- Moderate/severe: Until full recovery, often 2-4 weeks or longer, with lab tests (e.g., CRP, white blood cell count) confirming safety.
Never self-restart; risks include rebound inflammation or infection spread.[2][3]
Risks of pausing too long or restarting too soon
Pausing extended periods (>4-6 weeks) may reduce efficacy in psoriasis or psoriatic arthritis, leading to flare-ups. Restarting amid unresolved issues heightens infection risk (e.g., TB reactivation). Track symptoms daily and report to your doctor.[1][3]
When to call your doctor or seek emergency care
Contact immediately for fever >100.4°F, persistent diarrhea, severe rash, or breathing issues. ER for signs of sepsis, allergic reaction (swelling, hives), or IBD worsening. Don't pause without advice for chronic conditions.[2]
Alternatives if side effects force long pauses
Switch to biologics like Tremfya (guselkumab) or Skyrizi (risankizumab) if infections recur—fewer URI issues in trials. Topicals or methotrexate as bridges. Discuss with rheumatologist/dermatologist.[3]
[1] Cosentyx Prescribing Information, Novartis, https://www.cosentyx.com
[2] FDA Label for Secukinumab, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s035lbl.pdf
[3] American Academy of Dermatology Guidelines on Biologics, https://www.aad.org